Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
VISEN Pharmaceuticals ( (HK:2561) ) just unveiled an announcement.
VISEN Pharmaceuticals has scheduled a board meeting for 12 March 2026 to review and approve the group’s annual results for the financial year ended 31 December 2025 and to authorize their publication. The timing signals the company’s routine financial reporting cycle and will be closely watched by investors and other stakeholders for insight into VISEN’s recent operating performance and any accompanying strategic updates.
The announcement also reaffirms the current composition of VISEN’s board, led by executive director and CEO Lu An-Bang alongside non-executive and independent non-executive directors from diverse professional backgrounds. This governance disclosure underscores the company’s adherence to Hong Kong listing requirements and provides transparency around oversight as the board prepares to sign off on the latest set of annual results.
The most recent analyst rating on (HK:2561) stock is a Hold with a HK$38.00 price target. To see the full list of analyst forecasts on VISEN Pharmaceuticals stock, see the HK:2561 Stock Forecast page.
More about VISEN Pharmaceuticals
VISEN Pharmaceuticals is a Cayman Islands-incorporated biopharmaceutical company listed in Hong Kong, focusing on the development and commercialization of pharmaceutical products. The group operates through a board comprising executive, non-executive and independent non-executive directors, reflecting a standard governance structure for a listed pharma issuer.
Average Trading Volume: 25,291
Technical Sentiment Signal: Strong Sell
Current Market Cap: HK$3.73B
Find detailed analytics on 2561 stock on TipRanks’ Stock Analysis page.